Cinemark
CNK
36.42
+1.14
+3.23%
Cinemark
US · CNK
#2265 by market cap
Listed 1970
36.42
+1.14
+3.23%
Live - 5344 symbols - heartbeat 541s ago
· 2026-10-08 06:12
Pre-market
36.89
+1.29%
After-hours
36.42
0.00%
Overnight
36.89
+1.29%
- Market cap
- 4.22B
- P/E (TTM)i
- 20.35
- P/Bi
- 8.52
- EPSi
- 1.04
- Div yieldi
- 0.96%
- 52W posi
- 85%
Reader sentiment
Are you bullish or bearish on CNK?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.50, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +2.15% YoY
Margins
- Gross margin
- 64.13%
- Operating margin
- 10.97%
- Net margin
- 4.39%
Key ratios & quality
- Enterprise valuei
- 5.98B
- Altman Z-Scorei
- 1.50
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.22B | 3.28B | 686.30M | 1.51B | 2.45B | 3.07B | 3.05B | 3.12B |
| Gross profit | 2.04B | 2.07B | 450.90M | 997.60M | 1.58B | 1.98B | 1.96B | 2.00B |
| Selling & admin expenses | 1.32B | 1.40B | 552.40M | 674.00M | 858.60M | 931.60M | 945.20M | 969.00M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 459.43M | 407.40M | -590.80M | -224.70M | 77.00M | 371.80M | 362.40M | 341.80M |
| Pretax profit | 310.73M | 273.76M | -927.30M | -439.00M | -265.00M | 221.40M | 252.80M | 153.90M |
| Tax | 95.43M | 79.91M | -309.40M | -16.80M | 3.00M | 29.90M | -60.10M | 12.40M |
| Net profit | 215.31M | 193.85M | -617.90M | -422.20M | -268.00M | 191.50M | 312.90M | 141.50M |
| Basic EPS | 2 | 2 | -5 | -4 | -2 | 2 | 3 | 1 |
| Diluted EPS | 1.83 | 1.63 | -5.25 | -3.55 | -2.26 | 1.34 | 2.06 | 1.04 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 540.70M | 940.50M | 857.50M | 776.30M | 643.10M | 1.09B |
| Gross profit | 355.00M | 596.60M | 546.40M | 499.50M | 424.90M | 692.50M |
| Selling & admin expenses | 223.10M | 246.40M | 250.10M | 249.40M | 231.40M | 268.40M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -23.30M | 176.10M | 118.00M | 71.00M | 27.20M | 235.80M |
| Pretax profit | -53.30M | 137.20M | 27.60M | 42.40M | -9.80M | 203.20M |
| Tax | -14.70M | 42.50M | -22.90M | 7.50M | -4.00M | 62.40M |
| Net profit | -38.60M | 94.70M | 50.50M | 34.90M | -5.80M | 140.80M |
| Basic EPS | 0 | 1 | 0 | 0 | 0 | 1 |
| Diluted EPS | -0.32 | 0.63 | 0.40 | 0.16 | -0.06 | 1.19 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 559.03M | 634.99M | 892.75M | 874.40M | 863.60M | 1.06B | 1.30B | 598.70M |
| Cash & ST investments | 426.22M | 488.31M | 655.34M | 707.30M | 674.50M | 849.10M | 1.06B | 344.30M |
| Inventory | 19.32M | 21.69M | 12.59M | 15.50M | 23.70M | 23.30M | 31.00M | 29.10M |
| Total assets | 4.48B | 5.83B | 5.56B | 5.23B | 4.82B | 4.84B | 5.07B | 4.43B |
| Total current liabilities | 474.69M | 708.80M | 606.44M | 769.10M | 708.50M | 730.30M | 1.28B | 848.30M |
| Short-term debt | 35.05M | 239.43M | 291.42M | 287.90M | 244.40M | 234.30M | 691.80M | 237.90M |
| Long-term debt | 1.77B | 1.77B | 2.38B | 2.48B | 2.47B | 2.39B | 1.87B | 1.87B |
| Total liabilities | 3,073,268,000.00 | 4,379,695,000.00 | 4,763,953,000.00 | 4,896,100,000.00 | 4,698,200,000.00 | 4,518,000,000.00 | 4,463,600,000.00 | 4,020,100,000.00 |
| Total equity | 1.41B | 1.45B | 798.97M | 334.50M | 119.50M | 318.80M | 603.40M | 413.80M |
| Retained earnings | 638.91M | 687.33M | 27.94M | -389.40M | -660.60M | -472.40M | -162.70M | -64.40M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 894.40M | 1.24B | 766.10M | 598.70M | 486.70M | 761.30M |
| Cash & ST investments | 699.40M | 928.00M | 460.90M | 344.30M | 261.40M | 504.30M |
| Inventory | 30.90M | 33.20M | 30.00M | 29.10M | 32.50M | 32.30M |
| Total assets | 4.68B | 4.99B | 4.47B | 4.43B | 4.35B | 4.55B |
| Total current liabilities | 1.13B | 804.40M | 760.50M | 848.30M | 788.10M | 901.00M |
| Short-term debt | 693.10M | 237.30M | 238.10M | 237.90M | 239.70M | 238.30M |
| Long-term debt | 1.87B | 1.87B | 1.87B | 1.87B | 1.87B | 1.87B |
| Total liabilities | 4,324,600,000.00 | 3,986,500,000.00 | 3,907,100,000.00 | 4,020,100,000.00 | 3,956,100,000.00 | 4,048,500,000.00 |
| Total equity | 357.60M | 1.00B | 564.90M | 413.80M | 389.70M | 505.10M |
| Retained earnings | -211.70M | -185.10M | -633.40M | -64.40M | -81.60M | 47.10M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 556.92M | 562.00M | -330.10M | 166.20M | 136.00M | 444.30M | 466.00M | 396.10M |
| Depreciation & amortization | 261.16M | 261.16M | 259.80M | 265.40M | 238.20M | 209.50M | 197.50M | 201.90M |
| Free cash flow | 210.84M | 258.37M | -414.00M | 70.70M | 25.30M | 294.80M | 315.20M | 177.20M |
| Dividends paid | -149.49M | -159.28M | -42.30M | -- | -- | 0 | 0 | -38.90M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | 0 | 0 | -275.10M |
| Ending cash balance | 426.22M | 488.31M | 655.30M | 707.30M | 674.50M | 849.10M | 1.06B | 344.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -119.10M | 275.90M | 91.50M | 147.80M | -20.40M | 360.10M |
| Depreciation & amortization | 49.50M | 49.40M | 50.90M | 52.10M | 51.60M | 51.60M |
| Free cash flow | -141.20M | 245.80M | 38.10M | 34.50M | -58.10M | 298.50M |
| Dividends paid | -9.90M | -9.20M | -9.20M | -10.60M | -10.50M | -10.50M |
| Stock buybacks / issuance | -- | -- | 0 | -75.10M | -- | -- |
| Ending cash balance | 699.40M | 931.60M | 461.30M | 344.30M | 261.70M | 504.30M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 14.99 | 13.29 | -55.09 | -76.12 | -123.48 | 88.05 | 67.29 | 27.33 |
| ROA %i | 4.75 | 3.71 | -10.76 | -7.83 | -5.32 | 3.83 | 6.14 | 2.88 |
| ROIC %i | 8.57 | 6.59 | -10.78 | -5.84 | -3.49 | 7.41 | 9.94 | 6.75 |
| 5-year avg ROE %i | 18.74 | 17.95 | 3.01 | -16.29 | -44.97 | -30.41 | -19.65 | -3.17 |
| EBIT margin %i | 13.67 | 12.25 | -112.76 | -17.59 | -3.52 | 12.86 | 13.73 | 10.19 |
| FCF / sales %i | 6.54 | 7.87 | -- | 4.68 | 1.03 | 9.61 | 10.34 | 5.69 |
| Current ratioi | 1.18 | 0.90 | 1.47 | 1.14 | 1.22 | 1.45 | 1.01 | 0.71 |
| Quick ratioi | 1.11 | 0.81 | 1.39 | 1.07 | 1.11 | 1.35 | 0.95 | 0.62 |
| Debt / assetsi | 45.52 | 57.91 | 70.67 | 75.42 | 78.40 | 73.45 | 68.21 | 67.48 |
| LT debt / equityi | 143.61 | 218.40 | 461.93 | 1,132.61 | 3,205.63 | 1,071.14 | 465.06 | 679.64 |
| Interest coveragei | 3.40 | 3.13 | -5.04 | -1.53 | -0.48 | 2.28 | 2.52 | 1.94 |
| Revenue CAGR (3Y) %i | 4.14 | 4.00 | -38.78 | -22.31 | -9.24 | 64.71 | 26.39 | 8.26 |
| Net income CAGR (3Y) %i | -0.47 | -9.13 | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | 19.31 | 23.85 | -- | -30.53 | -53.91 | -- | 64.58 | 91.33 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 71.43 | 42.54 | 27.57 | 27.33 | 46.20 | 28.83 |
| ROA %i | 5.10 | 5.91 | 3.27 | 2.88 | 3.74 | 4.49 |
| ROIC %i | 8.63 | 9.88 | 6.96 | 6.75 | 8.62 | 9.16 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 12.24 | 14.44 | 10.83 | 10.19 | 11.10 | 12.34 |
| FCF / sales %i | 7.31 | 9.47 | 8.83 | 5.69 | 8.09 | 9.31 |
| Current ratioi | 0.79 | 1.54 | 1.01 | 0.71 | 0.62 | 0.84 |
| Quick ratioi | 0.72 | 1.44 | 0.91 | 0.62 | 0.52 | 0.75 |
| Debt / assetsi | 74.00 | 60.13 | 66.27 | 67.48 | 68.80 | 65.17 |
| LT debt / equityi | 793.79 | 278.43 | 490.29 | 679.64 | 721.70 | 550.60 |
| Interest coveragei | 2.21 | 2.71 | 2.05 | 1.94 | 2.24 | 2.74 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Admissions revenue is the largest reported line at 49.71% of revenue, across 4 reported segments.
- Concession revenue follows at 39.88%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Admissions revenue49.71%
Concession revenue39.88%
Other revenue6.28%
Screen advertising, screen rental and promotional revenue4.13%
Quote time 2026-10-08 06:12:05 · For reference only, not investment advice and not tailored to your situation.